NovMetaPharma Co., Ltd. (XKON:229500)

South Korea flag South Korea · Delayed Price · Currency is KRW
9,190.00
-210.00 (-2.23%)
At close: Apr 28, 2026
28.53%
Market Cap 118.01B
Revenue (ttm) 1.30B
Net Income (ttm) 408.03M
Shares Out 12.84M
EPS (ttm) 120.00
PE Ratio 76.58
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,983
Average Volume 8,652
Open 9,200.00
Previous Close 9,400.00
Day's Range 9,000.00 - 9,350.00
52-Week Range 6,800.00 - 17,890.00
Beta 0.22
RSI 41.02
Earnings Date n/a

About NovMetaPharma

NovMetaPharma Co., Ltd. engages in the development and sale of drugs to treat metabolic and fibrotic diseases in South Korea. It is developing Cyclo-Z, which is in phase 2 clinical stage; and CHP that is in phase 1 clinical stage for the treatment of diabetic kidney disease, obesity, and rare conditions, including FSHD and DMD. The company was formerly known as PNC MetaPharm Co., Ltd. and changed its name to NovMetaPharma Co., Ltd. in May 2015. NovMetaPharma Co., Ltd. was incorporated in 2010 and is headquartered in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 229500
Full Company Profile

Financial Performance

News

There is no news available yet.